SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

USO is drawing attention as crude prices climb amid reported Middle East shipping and energy-infrastructure attacks, fueling concerns about supply disruptions. Traders are divided between expecting the supply-risk rally to continue and anticipating a pullback if tensions ease; some also caution that the expiring WTI contract can distort comparisons with the next contract.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is under pressure after HSBC warned that heavy borrowing needs and potentially slower AI-compute demand could challenge its growth and returns, sharpening traders concerns about debt, refinancing, and dilution amid a broader neocloud selloff. Bears warn of credit and business-model risks, while bulls point to contracted demand and continued AI infrastructure growth; some also cite Goldman Sachss more positive view and ARKs share purchases.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares have slid to post-IPO lows amid concern over insider selling and successive lockup share releases, with traders also pointing to a TD Cowen price-target cut and questions about growth, scaling, and reliance on OpenAI. The discussion is sharply divided between calls for more downside and buyers arguing the selloff is overdone and the AI-chip technology has long-term potential.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius has been caught in a sharp neocloud and AI-infrastructure selloff as traders debate whether heavy buildout spending can earn adequate returns and whether financing risksespecially at CoreWeavewill spread across the sector. The community is split between treating the rebound after the decline as an oversold bounce and expecting more downside, while some argue Nebius is better positioned than debt-heavier peers and that compute demand remains strong.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale shares are under pressure after UBS downgraded the stock, citing long commercialization timelines and limited firm customer commitments, with uncertainty around the proposed TVA deployment adding to execution concerns. Traders are split between viewing the selloff as an overreaction and seeing it as confirmation of risks facing NuScale and the broader nuclear sector.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led rebound after the recent selloff, ahead of major megacap earnings, is driving QQQ discussion. Traders are divided over whether it marks a durable recovery or a relief rally that could fade, with AI investment and debt concerns and surging oil prices adding to caution.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GE Aerospaces third-quarter earnings beat and raised 2026 guidance are driving attention, with traders also citing stronger orders. Many view the report as bullish, while others are cautious about whether the stock can hold its post-earnings strength amid muted or weakening price action.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs quarterly earnings and revenue beat estimates, but traders are focused on the tightened full-year profit outlook rather than a larger guidance increase. The new buyback program is a positive offset for some, while others question why shares are falling despite the beat.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTX is drawing attention ahead of its Q3 earnings report, with traders anticipating a beat and stronger guidance while citing major missile and counter-drone awards as signs of sustained defense demand. Optimism about a rebound competes with concerns that expectations are high and contract wins have not always translated into stronger share performance.

Northrop Grumman Corp. engages in the provision of advanced aircraft systems. It operates through the following segments: Aeronautics Systems, Defense Systems, Mission Systems, and Space Systems. The Aeronautics Systems segment is involved in the design, development, production, integration, sustainment, and modernization of advanced aircraft systems for the U.S. Air Force, the U.S. Navy, other U.S. government agencies, and international customers. The Defense Systems segment includes integrated battle management systems, weapons systems and aircraft, and mission systems sustainment and modernization. The Mission Systems segment offers advanced mission solutions and multifunction systems, primarily for the U.S. defense and intelligence community, and international customers. The Space Systems segment delivers end-to-end mission solutions through the design, development, integration, production and operation of space, missile defense, launch and strategic missile systems for national security, civil government, commercial, and international customers. The company was founded by John K. Northrop, Thomas V. Jones, and Kent Kresa in 1939 and is headquartered in Falls Church, VA.

Northrop Grumman Corp.

Northrops Q3 results beat expectations and management raised its full-year outlook, with a record backlog reinforcing the growth case. Traders are debating why shares remain under pressure despite the strong report, pointing to margin and cash-flow concerns and the possibility that the positive news was already priced in.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HELP Stock Gaps Higher, Then Fades, On $35 Barclays Target Ahead Of Q4 Psychedelic Drug Trial Results

Equity

Barclays’ new price target of $35 implies an upside of about 150% from the stock’s last close on Thursday around $14.


HELP Stock Jumps 6% After TD Cowen Hikes Target Nearly 8x To $62  

TD Cowen lifted its target on HELP to $62 from $8 on Thursday, while maintaining a Buy rating.


CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners

Wells Fargo began coverage on five biotech stocks on Monday, with only Compass Pathways receiving an ‘Equal-Weight’ rating while the rest received ‘Overweight’ ratings.


HELP Stock Surges To Over 6-Month Highs Led By Crucial Phase 3 Milestone – Retail Expects It To Hit Fresh 52-Week Highs 

Helus Pharma said it completed enrollment ahead of schedule in the Phase 3 study evaluating HLP003 as an adjunctive treatment for major depressive disorder.


ATAI Stock Downgraded Across Wall Street – Why Analysts Believe Buyout By Eli Lilly Capped Near-Term Upside

H.C. Wainwright and Berenberg became the latest firms to downgrade the stock following Eli Lilly's acquisition agreement.


ATAI Stock Soars On Eli Lilly’s $2.8B Buyout – Why Are CMPS Shares Rising Too?

Both ATAI and CMPS stocks were among the top trending on Stocktwits in pre-market trade.


FDA Fast-Tracks Psychedelic Research After Trump’s Executive Order — CMPS, HELP Stocks Gain

The FDA stated that this will increase support for psychedelic-based medicines for the treatment of conditions like post-traumatic stress disorder, treatment-resistant depression, and major depressive disorder.

AdvisorShares Applauds Executive Order Accelerating Access to Psychedelic Therapies

AdvisorShares Applauds Executive Order Accelerating Access to Psychedelic Therapies AdvisorShares Applauds Executive Order Accelerating Access to Psychedelic Therapies PR Newswire BETHESDA, Md...

ENVB Stock Is On Track For Its Worst Decline In Over 10 Weeks On Discounted Offering – But Retail Remains Upbeat

Enveric stated during after-market hours on Thursday that it has entered into definitive agreements for the purchase and sale of 2.2 million shares of its common stock at a purchase price of $2.25.

ENVB Stock Dips After-Hours On Widening Q4 Loss Despite Study Progress On Psychiatry Drug

For the fourth quarter of 2025, the company reported net loss attributable of $4 million, higher than the loss of $3.2 billion reported for the corresponding quarter of 2024.


Advisorshares Trust - AdvisorShares Psychedelics ETF

Bearish Sentiment

<ul class="summary-bullets"><li>According to data from Koyfin, all 10 analysts covering HELP rate it a ‘Buy.’</li><li>Investors are now awaiting data from the late-stage APPROACH study of HLP003.&nbsp;</li><li>If the data hold, Helus aims to file an application with the U.S. Food and Drug Administration (FDA) seeking approval in 2028.</li></ul>Shares of Helus Pharma (HELP) opened on Friday at $15.15 and printed a new 52-week high before reversing gains after Barclays initiated coverage with an Overweight rating and a $35 price target ahead of upcoming trial results for its psychedelic drug.By midday, the stock was trading near $12.50, down about 11%, after touching a session low around $12.10.<h2 class="st-heading-2">Wall Street Takeaway</h2>Barclays’ new price target of $35 implies an upside of about 150% from the stock’s last close on Thursday around $14.Barclays is not far off consensus. According to data from Koyfin, all 10 analysts covering HELP rate it a ‘Buy.’ The 12-month average price target on the stock is $41.40, implying a potential upside of about 195%.<h2 class="st-heading-2">Near-Term Catalysts</h2>Helus develops novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways linked to neuroplasticity—for mental health conditions, mainly depression and anxiety.Investors are now awaiting data from the late-stage APPROACH study of HLP003 expected in the fourth quarter. The deuterated psilocin (the active form of psilocybin or the compound in magic mushrooms) drug is being tested as an add-on treatment for major depression and has FDA Breakthrough Therapy status. Enrollment finished in July.A second Phase 3 trial, EMBRACE, plus a long-term extension study, come after that readout. If the data hold, Helus aims to file an application with the U.S. Food and Drug Administration seeking approval in 2028. HLP004, a deuterated DMT (a short-acting psychedelic) candidate for anxiety, remains earlier-stage after a mid-stage signal-finding study.Helus closed a $50 million offering in late June to fund the late-stage work. Michael Halstead took the helm of the company in early August. Further, in mid-September, Executive Chair Eric So and Chief Growth Officer Paul Glavine each bought 100,000 shares on the open market, purchases of roughly $1.2 million apiece.<h2 class="st-heading-2">How Did HELP Retail Traders React?</h2>On Stocktwits, retail sentiment around HELP stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘extremely high’ levels.A Stocktwits user said that they added more shares today in light of the selloff.<stembedurl>https://stocktwits.com/GeorgeJetson17/message/664597609</stembedurl>Another reiterated confidence in the impact of psychedelic drugs on mental health.<stembedurl>https://stocktwits.com/Sibtsen/message/664590549</stembedurl><a href="https://stocktwits.com/symbol/HELP">HELP stock</a> has gained 53% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/len-arry-stocks-hit-new-lows-as-price-target-cuts-pile-up-what-s-driving-the-selloff/cZtHP4CRBEI">LEN, ARRY Stocks Hit New Lows As Price Target Cuts Pile Up — What’s Driving The Selloff?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Digitally generated image of brain filled with multicolored particles. | Source: Getty Images

According to data from Koyfin, all 10 analysts covering HELP rate it a ‘Buy.’Investors are now awaiting data from the late-stage APPROACH study of HLP003. If the data hold, Helus aims to file an application with the U.S. Food and Drug Administration (FDA)

Helus Pharma Inc.

AdvisorShares Psychedelics ETF

Invesco NASDAQ Future Gen 200 ETF

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$20.17
Prev Close	$19.90
Open	$20.00
Dividend Yield	N/A
50-Day Moving Average	$23.90
Beta	N/A
Avg. Volume	33,994.86
PE Ratio	N/A

52-Week High	$27.02
52-Week Low	$15.63
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

Feed

News

Sentiment

Fundamentals

Info

PSIL Fundamentals